GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (XTAE:KMDA) » Definitions » Cyclically Adjusted Revenue per Share

Kamada (XTAE:KMDA) Cyclically Adjusted Revenue per Share : ₪11.22 (As of Mar. 2025)


View and export this data going back to 2005. Start your Free Trial

What is Kamada Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kamada's adjusted revenue per share for the three months ended in Mar. 2025 was ₪2.730. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₪11.22 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Kamada's average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Kamada was 4.40% per year. The lowest was 4.40% per year. And the median was 4.40% per year.

As of today (2025-05-30), Kamada's current stock price is ₪23.96. Kamada's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₪11.22. Kamada's Cyclically Adjusted PS Ratio of today is 2.14.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kamada was 2.62. The lowest was 1.35. And the median was 1.87.


Kamada Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Kamada's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Cyclically Adjusted Revenue per Share Chart

Kamada Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 9.59 10.14 10.56 10.92

Kamada Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.80 10.93 10.99 10.92 11.22

Competitive Comparison of Kamada's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kamada's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kamada's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kamada's Cyclically Adjusted PS Ratio falls into.


;
;

Kamada Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kamada's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=2.73/134.9266*134.9266
=2.730

Current CPI (Mar. 2025) = 134.9266.

Kamada Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 1.732 100.684 2.321
201509 1.587 100.392 2.133
201512 2.447 99.792 3.309
201603 1.356 100.470 1.821
201606 1.690 101.688 2.242
201609 1.961 101.861 2.598
201612 2.123 101.863 2.812
201703 1.131 102.862 1.484
201706 3.057 103.349 3.991
201709 2.000 104.136 2.591
201712 2.287 104.011 2.967
201803 1.463 105.290 1.875
201806 2.927 106.317 3.715
201809 1.320 106.507 1.672
201812 4.496 105.998 5.723
201903 2.294 107.251 2.886
201906 3.023 108.070 3.774
201909 2.792 108.329 3.477
201912 2.702 108.420 3.363
202003 2.689 108.902 3.332
202006 3.361 108.767 4.169
202009 2.723 109.815 3.346
202012 2.440 109.897 2.996
202103 1.953 111.754 2.358
202106 1.817 114.631 2.139
202109 1.915 115.734 2.233
202112 2.718 117.630 3.118
202203 2.159 121.301 2.402
202206 1.902 125.017 2.053
202209 2.338 125.227 2.519
202212 3.339 125.222 3.598
202303 2.385 127.348 2.527
202306 2.903 128.729 3.043
202309 2.480 129.860 2.577
202312 2.242 129.419 2.337
202403 2.242 131.776 2.296
202406 2.696 132.554 2.744
202409 2.656 133.029 2.694
202412 2.219 133.157 2.248
202503 2.730 134.927 2.730

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Kamada  (XTAE:KMDA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kamada's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=23.96/11.22
=2.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kamada was 2.62. The lowest was 1.35. And the median was 1.87.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kamada Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Kamada's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kamada Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (XTAE:KMDA) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.